Authors: Chowdhury AT, Shahabz M, Karim MR, Islam J, Guo D, He D. DOI: https://doi.org/10.21203/rs.3.rs-38896/v1 Abstract Background The worldwide COVID-19 pandemic was caused by a newly discovered Coronavirus. The treatment methods for COVID-19 are emerging and rapidly evolving. Existing drugs, including Ivermectin and Hydroxychloroquine, offer the hope of effective treatment in early disease. In this [...]

Authors: Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. DOI:10.3329/jbcps.v38i0.47512 Abstract Background: A definitive treatment of SARS CoV-2 is yet toarrive and the human death toll rises exponentially globally.In this health emergency, it might be useful to look into theold therapies which could be effective against the virus. Invitro research showed [...]

Authors: Maurya DK DOI: 10.26434/chemrxiv.12630539.v1 D O I: 10.26434/chemrxiv.12630539.v1 [opens in a new tab] Abstract The current outbreak of the corona virus disease 2019 (COVID-19), has affected almost entire world and become pandemic now. Currently, there is neither any FDA approved drugs nor any vaccines available to control it. Very recently in Bangladesh, a group [...]

Authors: Sharun K, Dhama K, Patel SK, Pathak M, Tiwari R PMID: 32473642 PMCID: PMC7261036 DOI: 10.1186/s12941-020-00368-w Abstract The recent report by Caly et al., describing the antiviral potential of ivermectin against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro arrive to the agenda of potential candidates for COVID-19 treatment. This discovery gave [...]

Authors: Patel AN, Desai SS, Grainger DW, Mehra MR Abstract Importance: There is no established anti-viral therapy for treating COVID-19 illness. Objective: To study the usefulness of Ivermectin, an antimicrobial therapy, in COVID-19 outcomes. Design: An international, multicenter, observational propensity-score matched case-controlled study using prospectively collected data on patients diagnosed with [...]

Authors: Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. PMID: 32251768 PMCID: PMC7129059 DOI: 10.1016/j.antiviral.2020.104787 Abstract Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum [...]

Authors: Yang SN, Atkinson SC, Wang C, Lee A PMID: 32135219 DOI: 10.1016/j.antiviral.2020.104760 Abstract Infection by RNA viruses such as human immunodeficiency virus (HIV)-1, influenza, and dengue virus (DENV) represent a major burden for human health worldwide. Although RNA viruses replicate in the infected host cell cytoplasm, the nucleus is central to key stages of [...]

Authors: Liu J, Liang H, Chen C, Wang X, Qu F, Wang H PMID: 31755894 PMCID: PMC6900471 DOI: 10.1042/BSR20192489 Abstract Glioma is one of the most common types of primary brain tumors. Ivermectin (IVM), a broad-spectrum antiparasitic drug, has been identified as a novel anticancer agent due to its inhibitory effects on the proliferation of [...]

Cutaneous adverse reactions to medications are extremely common and display characteristic clinical morphology. A fixed drug eruption is a cutaneous adverse drug reaction due to type IV or delayed cell-mediated hypersensitivity. Ivermectin, a broad-spectrum anti-parasitic compound, has been an essential component of public health campaigns targeting the control of two devastating neglected tropical diseases: onchocerciasis (river blindness) and lymphatic filariasis.

Ivermectin is a pivotal drug for the control of onchocerciasis and lymphatic filariasis, which is increasingly identified as a useful drug for the control of other Neglected Tropical Diseases.